Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, w...
Saved in:
Published in | International journal of molecular sciences Vol. 23; no. 24; p. 16206 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
19.12.2022
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib. To identify specific adverse effects related to the background of cirrhosis, we used a diethylnitrosamine (DEN)-induced cirrhotic rat model. Vevorisertib was tested in vitro on Hep3B, HepG2, HuH7 and PLC/PRF cell lines. Rats were treated weekly with intra-peritoneal injections of DEN for 14 weeks to obtain cirrhosis with fully developed HCC. After that, rats were randomized into four groups (n = 7/group): control, sorafenib, vevorisertib and the combination of vevorisertib + sorafenib, and treated for 6 weeks. Tumor progression was followed by MRI. We demonstrated that the vevorisertib is a highly potent treatment, blocking the phosphorylation of AKT. The tumor progression in the rat liver was significantly reduced by treatment with vevorisertib + sorafenib (49.4%) compared to the control group (158.8%, p < 0.0001). Tumor size, tumor number and tumor cell proliferation were significantly reduced in both the vevorisertib group and vevorisertib + sorafenib groups compared to the control group. Sirius red staining showed an improvement in liver fibrosis by vevorisertib and the combination treatment. Moreover, vevorisertib + sorafenib treatment was associated with a normalization in the liver vasculature. Altogether, vevorisertib as a single agent and its combination with sorafenib exerted a strong suppression of tumor progression and improved liver fibrosis. Thus, results provide a rationale for testing vevorisertib in clinical settings and confirm the importance of targeting AKT in HCC. |
---|---|
AbstractList | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib. To identify specific adverse effects related to the background of cirrhosis, we used a diethylnitrosamine (DEN)-induced cirrhotic rat model. Vevorisertib was tested in vitro on Hep3B, HepG2, HuH7 and PLC/PRF cell lines. Rats were treated weekly with intra-peritoneal injections of DEN for 14 weeks to obtain cirrhosis with fully developed HCC. After that, rats were randomized into four groups (
n
= 7/group): control, sorafenib, vevorisertib and the combination of vevorisertib + sorafenib, and treated for 6 weeks. Tumor progression was followed by MRI. We demonstrated that the vevorisertib is a highly potent treatment, blocking the phosphorylation of AKT. The tumor progression in the rat liver was significantly reduced by treatment with vevorisertib + sorafenib (49.4%) compared to the control group (158.8%,
p
< 0.0001). Tumor size, tumor number and tumor cell proliferation were significantly reduced in both the vevorisertib group and vevorisertib + sorafenib groups compared to the control group. Sirius red staining showed an improvement in liver fibrosis by vevorisertib and the combination treatment. Moreover, vevorisertib + sorafenib treatment was associated with a normalization in the liver vasculature. Altogether, vevorisertib as a single agent and its combination with sorafenib exerted a strong suppression of tumor progression and improved liver fibrosis. Thus, results provide a rationale for testing vevorisertib in clinical settings and confirm the importance of targeting AKT in HCC. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib. To identify specific adverse effects related to the background of cirrhosis, we used a diethylnitrosamine (DEN)-induced cirrhotic rat model. Vevorisertib was tested in vitro on Hep3B, HepG2, HuH7 and PLC/PRF cell lines. Rats were treated weekly with intra-peritoneal injections of DEN for 14 weeks to obtain cirrhosis with fully developed HCC. After that, rats were randomized into four groups (n = 7/group): control, sorafenib, vevorisertib and the combination of vevorisertib + sorafenib, and treated for 6 weeks. Tumor progression was followed by MRI. We demonstrated that the vevorisertib is a highly potent treatment, blocking the phosphorylation of AKT. The tumor progression in the rat liver was significantly reduced by treatment with vevorisertib + sorafenib (49.4%) compared to the control group (158.8%, p < 0.0001). Tumor size, tumor number and tumor cell proliferation were significantly reduced in both the vevorisertib group and vevorisertib + sorafenib groups compared to the control group. Sirius red staining showed an improvement in liver fibrosis by vevorisertib and the combination treatment. Moreover, vevorisertib + sorafenib treatment was associated with a normalization in the liver vasculature. Altogether, vevorisertib as a single agent and its combination with sorafenib exerted a strong suppression of tumor progression and improved liver fibrosis. Thus, results provide a rationale for testing vevorisertib in clinical settings and confirm the importance of targeting AKT in HCC. |
Author | Abbadessa, Giovanni Lerat, Herve Yu, Yi Zeybek Kuyucu, Ayca Kurma, Keerthi Roth, Gaël S Mercey-Ressejac, Marion Decaens, Thomas Macek Jilkova, Zuzana Sturm, Nathalie Marche, Patrice N |
AuthorAffiliation | 4 T-RAIG, TIMC, University Grenoble-Alpes/CNRS UMR5525, 38700 La Tronche, France 6 Unité Mixte de Service hTAG, Grenoble Alpes University, Inserm US046, CNRS UAR2019, 38700 La Tronche, France 3 Pathology and Cytology Department, CHU Grenoble Alpes, 38700 Grenoble, France 2 Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, 38700 Grenoble, France 1 Institute for Advanced Biosciences, University Grenoble Alpes, CNRS UMR5309, INSERM U1209, 38700 Grenoble, France 5 ArQule Inc., Burlington, MA 01803, USA |
AuthorAffiliation_xml | – name: 2 Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, 38700 Grenoble, France – name: 4 T-RAIG, TIMC, University Grenoble-Alpes/CNRS UMR5525, 38700 La Tronche, France – name: 6 Unité Mixte de Service hTAG, Grenoble Alpes University, Inserm US046, CNRS UAR2019, 38700 La Tronche, France – name: 1 Institute for Advanced Biosciences, University Grenoble Alpes, CNRS UMR5309, INSERM U1209, 38700 Grenoble, France – name: 3 Pathology and Cytology Department, CHU Grenoble Alpes, 38700 Grenoble, France – name: 5 ArQule Inc., Burlington, MA 01803, USA |
Author_xml | – sequence: 1 givenname: Keerthi surname: Kurma fullname: Kurma, Keerthi organization: Institute for Advanced Biosciences, University Grenoble Alpes, CNRS UMR5309, INSERM U1209, 38700 Grenoble, France – sequence: 2 givenname: Ayca surname: Zeybek Kuyucu fullname: Zeybek Kuyucu, Ayca organization: Institute for Advanced Biosciences, University Grenoble Alpes, CNRS UMR5309, INSERM U1209, 38700 Grenoble, France – sequence: 3 givenname: Gaël S orcidid: 0000-0001-5822-4320 surname: Roth fullname: Roth, Gaël S organization: Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, 38700 Grenoble, France – sequence: 4 givenname: Nathalie surname: Sturm fullname: Sturm, Nathalie organization: T-RAIG, TIMC, University Grenoble-Alpes/CNRS UMR5525, 38700 La Tronche, France – sequence: 5 givenname: Marion orcidid: 0000-0003-0667-2513 surname: Mercey-Ressejac fullname: Mercey-Ressejac, Marion organization: Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, 38700 Grenoble, France – sequence: 6 givenname: Giovanni surname: Abbadessa fullname: Abbadessa, Giovanni organization: ArQule Inc., Burlington, MA 01803, USA – sequence: 7 givenname: Yi surname: Yu fullname: Yu, Yi organization: ArQule Inc., Burlington, MA 01803, USA – sequence: 8 givenname: Herve surname: Lerat fullname: Lerat, Herve organization: Unité Mixte de Service hTAG, Grenoble Alpes University, Inserm US046, CNRS UAR2019, 38700 La Tronche, France – sequence: 9 givenname: Patrice N orcidid: 0000-0002-8930-9340 surname: Marche fullname: Marche, Patrice N organization: Institute for Advanced Biosciences, University Grenoble Alpes, CNRS UMR5309, INSERM U1209, 38700 Grenoble, France – sequence: 10 givenname: Thomas orcidid: 0000-0003-0928-0048 surname: Decaens fullname: Decaens, Thomas organization: Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, 38700 Grenoble, France – sequence: 11 givenname: Zuzana orcidid: 0000-0002-2553-5971 surname: Macek Jilkova fullname: Macek Jilkova, Zuzana organization: Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, 38700 Grenoble, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36555845$$D View this record in MEDLINE/PubMed https://cnrs.hal.science/hal-04651076$$DView record in HAL |
BookMark | eNpdkkuP0zAQgCO0iH3AkSuyxIU9FGzHj_iCVFW7tKKAxFZcLceZtK4SuzhuET-Df4xDl9V2T7ZmvvnsGc1lceaDh6J4TfD7slT4g9v2Ay0pI4Ji8ay4IIzSCcZCnj26nxeXw7DFOINcvSjOS8E5rxi_KP7ctC3YhEKLvoYDdGj6eYUWfuNql0JEP-AQohsgJlcjM6A759cdoOkafELGN8h5NAt97bxJLnj0y6UNugvRtOBzRY7MYWdSsNB1-85ENDPROh96M1YaNHMxbkJyFn03CX0JDXQvi-et6QZ4dX9eFavbm9VsPll--7SYTZcTywlPE0Jr1VBoTcl5a4RtFG4pWFCsaSomy5ziRDFBKZNgFAiJQbBKylZIoVh5VSyO2iaYrd5F15v4Wwfj9L9AiGttcte2Ay0Y0BoaLhW3zIA1uMakUpRwWVtZQXZ9PLp2-7qHxubhRNOdSE8z3m30Ohy0khUrWZUF10fB5knZfLrUYwwzwQmW4kAy--7-sRh-7mFIunfDOF_jIewHTSWvCM7eEX37BN2GffR5qiMlZFkJLjM1OVI2hmGI0D78gGA97pg-2bHMv3nc7QP9f6nKv1AfzwY |
CitedBy_id | crossref_primary_10_4291_wjgp_v14_i3_46 crossref_primary_10_3390_ijms24109018 crossref_primary_10_1080_15376516_2024_2332909 crossref_primary_10_3389_fmed_2024_1389329 crossref_primary_10_3390_ijms24043441 crossref_primary_10_3390_ijms25041973 |
Cites_doi | 10.1097/CCO.0000000000000812 10.3390/cancers12061663 10.1016/j.bbapap.2003.11.009 10.3390/cancers14040940 10.1038/s41416-020-0889-4 10.3390/biomedicines9111639 10.3390/cancers13194981 10.1016/j.coph.2008.08.004 10.1007/s12032-009-9201-4 10.1016/S0140-6736(22)01200-4 10.18632/oncotarget.24298 10.1126/scitranslmed.aay3724 10.3892/or.2013.2932 10.3390/cells11132051 10.3390/ijms22041794 10.3390/cancers14122880 10.21873/anticanres.15728 10.1016/j.jhep.2010.07.004 10.1016/j.pharmthera.2016.12.001 10.3390/cancers13163949 10.1016/j.ejphar.2022.175186 10.1158/1535-7163.MCT-16-0602-T 10.1371/journal.pone.0140479 10.1002/hep.22506 |
ContentType | Journal Article |
Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License 2022 by the authors. 2022 |
Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License – notice: 2022 by the authors. 2022 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 1XC VOOES 5PM DOA |
DOI | 10.3390/ijms232416206 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Research Library Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1422-0067 1661-6596 |
ExternalDocumentID | oai_doaj_org_article_64e2bed5795c4aeca0b01892157bc78e oai_HAL_hal_04651076v1 10_3390_ijms232416206 36555845 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Fonds Agir pour les Maladies Chroniques grantid: 2018 – fundername: La Ligue contre le cancer InterRégion AuRA grantid: 38-2017 – fundername: Fonds Agir pour les Maladies Chroniques – fundername: La Ligue contre le cancer InterRégion AuRA |
GroupedDBID | --- 29J 2WC 3V. 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH ABDBF ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV AEAQA AENEX AFKRA AFPKN AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CS3 CUY CVF D1I DIK DU5 DWQXO E3Z EBD EBS ECM EIF EJD ESTFP ESX F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HH5 HMCUK HYE IAO ITC KB. KQ8 LK8 M1P M2O M48 M7P MODMG M~E NPM O5R O5S OK1 P2P PDBOC PIMPY PQQKQ PROAC PSQYO RIG RNS RPM TR2 TUS UKHRP ~8M AAYXX CITATION 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 7X8 1XC ADRAZ C1A IPNFZ VOOES 5PM |
ID | FETCH-LOGICAL-c515t-12b9d2efa355fa6cd90f2ece94dd84732ef519462247ea9e670e64877f676943 |
IEDL.DBID | RPM |
ISSN | 1422-0067 1661-6596 |
IngestDate | Fri Jul 05 11:57:18 EDT 2024 Tue Sep 17 21:32:16 EDT 2024 Wed Sep 04 07:24:18 EDT 2024 Wed Jul 24 14:04:44 EDT 2024 Fri Sep 13 08:18:32 EDT 2024 Wed Aug 14 12:35:45 EDT 2024 Sat Sep 28 08:18:54 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 24 |
Keywords | HCC DEN-induced cirrhotic rat model of HCC fibrosis liver vevorisertib AKT pathway |
Language | English |
License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c515t-12b9d2efa355fa6cd90f2ece94dd84732ef519462247ea9e670e64877f676943 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC9784348 |
ORCID | 0000-0002-2553-5971 0000-0001-5822-4320 0000-0002-8930-9340 0000-0003-0928-0048 0000-0003-0667-2513 0000-0002-8505-378X |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784348/ |
PMID | 36555845 |
PQID | 2756738657 |
PQPubID | 2032341 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_64e2bed5795c4aeca0b01892157bc78e pubmedcentral_primary_oai_pubmedcentral_nih_gov_9784348 hal_primary_oai_HAL_hal_04651076v1 proquest_miscellaneous_2758108431 proquest_journals_2756738657 crossref_primary_10_3390_ijms232416206 pubmed_primary_36555845 |
PublicationCentury | 2000 |
PublicationDate | 20221219 |
PublicationDateYYYYMMDD | 2022-12-19 |
PublicationDate_xml | – month: 12 year: 2022 text: 20221219 day: 19 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | International journal of molecular sciences |
PublicationTitleAlternate | Int J Mol Sci |
PublicationYear | 2022 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Tan (ref_12) 2022; 931 Llovet (ref_7) 2008; 48 Zhou (ref_8) 2010; 27 ref_14 ref_13 Brown (ref_5) 2017; 172 ref_11 ref_10 Kunter (ref_25) 2014; 31 Hettiarachchi (ref_24) 2020; 12 ref_17 Vogel (ref_1) 2022; 400 ref_23 ref_20 Hanada (ref_4) 2004; 1697 Yap (ref_3) 2008; 8 Zhang (ref_9) 2018; 15 Kuyucu (ref_15) 2018; 9 Yang (ref_19) 2022; 42 Ghelfi (ref_2) 2022; 34 ref_26 Roth (ref_16) 2017; 16 Thabut (ref_21) 2010; 53 Qu (ref_22) 2015; 6 Kostaras (ref_18) 2020; 123 ref_6 |
References_xml | – volume: 34 start-page: 155 year: 2022 ident: ref_2 article-title: Immunomodulation for hepatocellular carcinoma therapy: Current challenges publication-title: Curr. Opin. Oncol. doi: 10.1097/CCO.0000000000000812 contributor: fullname: Ghelfi – ident: ref_10 doi: 10.3390/cancers12061663 – volume: 1697 start-page: 3 year: 2004 ident: ref_4 article-title: Structure, regulation and function of PKB/AKT--a major therapeutic target publication-title: Biochim. Et Biophys. Acta doi: 10.1016/j.bbapap.2003.11.009 contributor: fullname: Hanada – ident: ref_23 doi: 10.3390/cancers14040940 – volume: 123 start-page: 542 year: 2020 ident: ref_18 article-title: A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity publication-title: Br. J. Cancer doi: 10.1038/s41416-020-0889-4 contributor: fullname: Kostaras – ident: ref_13 doi: 10.3390/biomedicines9111639 – ident: ref_17 doi: 10.3390/cancers13194981 – volume: 8 start-page: 393 year: 2008 ident: ref_3 article-title: Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2008.08.004 contributor: fullname: Yap – volume: 27 start-page: 255 year: 2010 ident: ref_8 article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma publication-title: Med. Oncol. (Northwood Lond. Engl.) doi: 10.1007/s12032-009-9201-4 contributor: fullname: Zhou – volume: 400 start-page: 1345 year: 2022 ident: ref_1 article-title: Hepatocellular carcinoma publication-title: Lancet doi: 10.1016/S0140-6736(22)01200-4 contributor: fullname: Vogel – volume: 15 start-page: 9377 year: 2018 ident: ref_9 article-title: Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma publication-title: Oncol. Lett. contributor: fullname: Zhang – volume: 6 start-page: 300 year: 2015 ident: ref_22 article-title: New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials publication-title: Front. Pharmacol. contributor: fullname: Qu – volume: 9 start-page: 11145 year: 2018 ident: ref_15 article-title: Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.24298 contributor: fullname: Kuyucu – volume: 12 start-page: eaay3724 year: 2020 ident: ref_24 article-title: Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aay3724 contributor: fullname: Hettiarachchi – volume: 31 start-page: 573 year: 2014 ident: ref_25 article-title: Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma publication-title: Oncol. Rep. doi: 10.3892/or.2013.2932 contributor: fullname: Kunter – ident: ref_26 doi: 10.3390/cells11132051 – ident: ref_20 doi: 10.3390/ijms22041794 – ident: ref_11 doi: 10.3390/cancers14122880 – volume: 42 start-page: 2495 year: 2022 ident: ref_19 article-title: Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib publication-title: Anticancer Res. doi: 10.21873/anticanres.15728 contributor: fullname: Yang – volume: 53 start-page: 976 year: 2010 ident: ref_21 article-title: Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension? publication-title: J. Hepatol. doi: 10.1016/j.jhep.2010.07.004 contributor: fullname: Thabut – volume: 172 start-page: 101 year: 2017 ident: ref_5 article-title: Maximising the potential of AKT inhibitors as anti-cancer treatments publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2016.12.001 contributor: fullname: Brown – ident: ref_6 doi: 10.3390/cancers13163949 – volume: 931 start-page: 175186 year: 2022 ident: ref_12 article-title: FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2022.175186 contributor: fullname: Tan – volume: 16 start-page: 2157 year: 2017 ident: ref_16 article-title: Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0602-T contributor: fullname: Roth – ident: ref_14 doi: 10.1371/journal.pone.0140479 – volume: 48 start-page: 1312 year: 2008 ident: ref_7 article-title: Molecular targeted therapies in hepatocellular carcinoma publication-title: Hepatology (Baltim. Md.) doi: 10.1002/hep.22506 contributor: fullname: Llovet |
SSID | ssj0023259 |
Score | 2.4319165 |
Snippet | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a... |
SourceID | doaj pubmedcentral hal proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 16206 |
SubjectTerms | AKT pathway AKT protein Allosteric properties Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Carcinoma, Hepatocellular - metabolism Cell cycle Cell growth Cell Line, Tumor Cell Proliferation Cirrhosis DEN-induced cirrhotic rat model of HCC Diethylnitrosamine Fibrosis HCC Hepatitis Hepatocellular carcinoma Human health and pathology Hépatology and Gastroenterology Kinases Life Sciences Liver Liver cancer Liver cirrhosis Liver Cirrhosis - drug therapy Liver diseases Liver Neoplasms - metabolism Medical prognosis Model testing Mutation Niacinamide - pharmacology Niacinamide - therapeutic use Pharmaceutical sciences Pharmacology Phenylurea Compounds - pharmacology Phenylurea Compounds - therapeutic use Phosphorylation Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Proto-Oncogene Proteins c-akt - metabolism Rats Sorafenib - pharmacology Sorafenib - therapeutic use Targeted cancer therapy Tumors Tyrosine vevorisertib |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNH26SYNaSm8msixL1nG7JGwf5NBsS25GtmTWJZGD11nIz-g_7ozsXdbtoZeCT3rYQjPjmRGj7yPkfcVzw3WmYqOtioURPNaZZnECpqSYzRg3Ae3zQi6-i89X2dUe1RfWhA3wwMPGnUrheOlspnRWCeMqgyd3uQZPpcpK5S78fZNsm0yNqVbKA01aAt4nlpmWA7pmCgn-afPzZo1hRCI50hzteaMA2g8-ZoUlkX_Hm3-WTe75ofMn5PEYQNLZsPBD8sD5p-ThQCl5_4z8GuCIaVvTi3bjYOCXJf3kV00JptvRH27Tdki_3DclNWt6CZ7r2tEZXrCixlvaeAq_CEiXg8QoHtPSS1CT2nmYAS0L8F99i-f9WMBK58hF5NsbgzMNnTddt2phafSb6SkSrV0_J8vzs-V8EY-0C3EFwU0fJ7zUlrvaQChSG1lZzWruKqeFteDLUuiCsE9IcP7KGe2kYk5C3qNqLJcV6Qty4FvvXhHKjU5FyapE8FI4pk0tSyshqrBKQVqpI_Jhu_vF7QCuUUBSgmIqJmKKyEeUzW4QYmKHBtCUYtSU4l-aEpF3INnJOxazrwW2MWSEZ0pukogcbwVfjNa8LhAiP5Cjqoi83XWDHeJmG-_auzAmT1gO8VhEXg56svtUKhFVTWQRURMNmqxl2uObVcD6hiRfpCJ__T824Ig84nh5I4FHH5ODvrtzbyCk6suTYD2_AZCjHe8 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfGJiReEN8EBjII8RbVcRw7fkJdtSl8qEJbQXuLHNuhQVsy0qwSfwb_MXdJWlaQkPpkO62bu_P9zj7fj5A3lqeG60SFRjsVCiN4qBPNwghMSTGXMG76ap9zmX0RH86T8z2Sbe7CYFrlZk3sF2rXWNwjn2CZ8p6gUk1MgbsAtpu8u_oRIn8UnrOOZBq3yAGPBB7YHhwdzz-fboOvmPfEaRH4o1AmWg71NmMI-SfV98sVAotIciQ-uuGf-jL-4HWWmCT5LwL9O5Hyhmc6uUfujpCSTgcduE_2fP2A3B5IJn8-JL-GAsW0Kem8WXsY-HFB39fLqgBjbulXv4Y_h2fyVUHNip6BL7vwdIpXrqipHa1qCosGBNC9DClu3NIzUJzS1_AEtGTg0boGTwAwpZXOkJ2obi4NPmnorGrbZQNTo6emo0i9dvGILE6OF7MsHIkYQgtwpwsjXmjHfWkAnJRGWqdZyb31WjgH3i2GLgCCQgIcUN5oLxXzEiIhVWICrYgfk_26qf1TQrnRsSiYjQQvhGfalLJwEnCGUwoCTR2Qt5u3n18N5TZyCFNQTPmOmAJyhLLZDsIq2X1D037LR6PLpfC88C5ROrHCeGtw1zfVgHJUYVXqA_IaJLvzHdn0U45tDDnimZLrKCCHG8Hno32v8j_aGJBX226wTHzZpvbNdT8mjVgKCC0gTwY92f5ULLHOmkgConY0aGcuuz11teyrf0PYL2KRPvv_tJ6TOxwvakTw0Ydkv2uv_QuAT13xcrSM3619Gi8 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQIiQuiDeBBRmEuAUcx7HjA0KlYlVee2C7aG-REzs0qOtAmq3Yn8E_ZsZpC2E5IuXkRxJ5ZjLfJM73EfK04rnhOlOx0VbFwgge60yzOIFQUsxmjJvA9nkoZ8fi3Ul28ptSaLOAq3-Wdqgnddwtn__4fv4KAv4lVpxQsr9ovp6uEBgkkiP59mUuUoHO_lHsPihAd9BNSyAdxTLTcqDbvDh9lJ4Ciz8knQXukbwIQP_eR_lHYjq4Tq5tECWdDC5wg1xy_ia5MmhMnt8iPwd-YtrW9LBdOxj4fk7f-kVTQix39LNbtx3qMfdNSc2KHkEqWzo6wT-uqPGWNp7CMwPq52BCiu9t6RH4Te08zICWGSS0vsUPALijlU5RnMi3pwZnGjptum7Rwq3RT6anqLy2vE3mB2_m01m80WGIK0A7fZzwUlvuagPYpDaysprV3FVOC2shuaXQBThQSEADyhntpGJOQiGkatw_K9I7ZM-33t0jlBudipJVieClcEybWpZWAsywSkGdqSPybLv6xbeBbaOAKgXNVIzMFJHXaJvdICTJDg1t96XYxFwhheOls5nSWSWMqwy-9M01gBxVVip3EXkClh2dYzb5UGAbQ4l4puQ6icj-1vDF1jsL5MwPaqkqIo933RCYuNjGu_YsjMkTlgNAi8jdwU92l0ol0qyJLCJq5EGjexn3-GYRyL-h6gf3zu__jwV4QK5y_JsjgUPvk72-O3MPAWP15aMQPb8AJ5MlFQ priority: 102 providerName: Scholars Portal |
Title | Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36555845 https://www.proquest.com/docview/2756738657/abstract/ https://search.proquest.com/docview/2758108431 https://cnrs.hal.science/hal-04651076 https://pubmed.ncbi.nlm.nih.gov/PMC9784348 https://doaj.org/article/64e2bed5795c4aeca0b01892157bc78e |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBbaDgN2Gfae2y7QhmE3N7IsS9YxDZpljwZFmw25GbItLx4Su3DcAPsZ-8cj_Qia7TbA8EEPWzBJ86NAfSTkfcJDw3WgXKNT5QojuKsDzVwPTEmxNGDcNGyfMzn9Jj4vgsUBCfqzME3SfhLnZ8VqfVbkyya38nadDPs8seHV5RgiH-GLcHhIDpXv9yF6F2X5AOhbMk0f4vlh_nO9QdTgSc6wXpEvkeEKTy_d80MNXT94lyUmQ_6LNP9OmLzngSZPyOMOOtJRu8Sn5MAWz8jDtpjkr-fkd0tETMuMzsqthYFf5vRTscxjMNqKfrfbssLCy3UeU7OhN-CzVpaO8GgVNUVK84LCzwEC5UZWFDdo6Q0oSGYLmAEtU_BcdYk7_Zi6SsdYhago1wZnGjrOq2pZwtLotakpllhbvSDzycV8PHW7ggtuArCmdj0e65TbzAAIyYxMUs0ybhOrRZqCF_OhCwCfkOD2lTXaSsWshIhHZZgoK_yX5KgoC_uaUG60L2KWeILHwjJtMhmnEvBEqhQElNohH_qvH922tBoRhCMosWhPYg45R9nsBiEbdtNQVj-iTiciKSyPbRooHSTC2MTg7m6oAc2oOFGhdcg7kOzeM6ajrxG2MawFz5Tceg457QUfdXa8iZAcvymLqhzydtcNFogf2xS2vGvGhB4DjYRHvGr1ZPeqXtscovY0aG8t-z2g9A3Ld6fkx_8984Q84nhWw4NLn5KjurqzbwBB1fEA7Gah4B5OPg7Ig_OL2dX1oNmNGKBnC-B-KcJBY1d_AJfTIkM |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,12792,21416,24346,27957,27958,31754,31755,33408,33409,33779,33780,43345,43635,43840,53827,53829,74102,74392,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fj5QwEG70jNEX488TPbUa4xu5UkpLn8y68cJ56z54q9k3UmhxMXdwstwm_hn-x84Au3doYsJTW6Awnc43wzAfIW9zHhuuI-UbbZUvjOC-jjTzA1AlxWzEuOmqfc5l8lV8WkbLIeC2HtIqt3tit1HbOscY-SGWKe8IKtX7i58-skbh19WBQuMmuSXCUGBKn1peOVwh78jSArBBvoy07GtshuDmH5Y_ztcIJgLJkezomk3qSveDpVlhYuS_qPPv5Mlr1ujoPrk3wEg66eX-gNxw1UNyuyeW_PWI_O6LEtO6oPN642DgyYIeV6syAwVu6De3gUfD7_BlRs2anoL9OnN0gr9ZUVNZWlYUNgpwmju5UQzW0lNYLIWr4AxoScCKtTVG_TGNlU6Rkaiqzw2eaei0bJpVDVOjX0xLkW7t7DFZHH1cTBN_IF_wc4A4rR_wTFvuCgOApDAyt5oV3OVOC2vBooXQBeBPSIAAyhntpGJOgvejCkyaFeETslfVlXtKKDc6FBnLA8Ez4Zg2hcysBGxhlQLnUnvk3fbtpxd9iY0UXBMUUzoSk0c-oGx2g7AydtdQN9_TQdFSKRzPnI2UjnJhXG4w0htrQDYqy1XsPPIGJDu6RjKZpdjGkBeeKbkJPHKwFXw66PQ6vVqBHnm96wZtxJdtKldfdmPigMWAyjyy36-T3a1CibXVROQRNVpBo7mMe6py1VX8BldfhCJ-9v9pvSJ3ksXnWTo7np88J3c5_qgRwKEPyF7bXLoXAJ_a7GWnI38A_b4X_A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgE4gXxG8CAwxCvEVNHMeOn1BXVnVsqqatoL1FTuzQoM0ZaVaJP4P_mLskLQtISH2yndTJ3fm-sy_3EfI-Z4lmKpa-Vkb6XHPmq1gFfgimJAMTB0y31T7nYvaFfz6Pz_v8p1WfVrlZE9uF2lQ57pGPsEx5S1ApR0WfFnHyafrx6oePDFJ40trTadwmu5KLGDR8d_9gfnK6Db8i1lKnheCRfOgXXcXNCIL-Ufn9coXQIhQMqY9ueKi2kD_4nSWmSf6LQf9Opbzhm6YPyP0eVNJxpwUPyS3rHpE7Hc3kz8fkV1eimFYFnVdrCwOPFvTQLcsMzLmmX-0aHg5P5cuM6hU9A292YekYP7qi2hlaOgrLBoTQrRQpbt3SM1Cdwjq4Alpm4NOaCs8AMKmVTpCfyFWXGq_UdFLW9bKCqdFT3VAkX7t4QhbTg8Vk5vdUDH4OgKfxQ5Ypw2yhAZ4UWuRGBQWzuVXcGPBvEXQBFOQCAIG0WlkhAysgFpIFptDy6CnZcZWzzwllWkU8C_KQs4zbQOlCZEYA0jBSQqipPPJh8_bTq67gRgqBCoopHYjJI_som-0grJPdNlT1t7Q3u1RwyzJrYqninGuba9z3TRTgHJnlMrEeeQeSHdxjNj5OsS1AlvhAinXokb2N4NPewlfpH330yNttN9gmvmztbHXdjknCIAGM5pFnnZ5s_yoSWGmNxx6RAw0azGXY48plW_8bAn8e8eTF_6f1htwFA0mPD-dHL8k9hl9thPBTe2Snqa_tK8BSTfa6N5LfCKkdnw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Novel+AKT+Inhibitor+Vevorisertib+as+Single+Agent+and+in+Combination+with+Sorafenib+on+Hepatocellular+Carcinoma+in+a+Cirrhotic+Rat+Model&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Keerthi+Kurma&rft.au=Ayca+Zeybek+Kuyucu&rft.au=Ga%C3%ABl+S.+Roth&rft.au=Nathalie+Sturm&rft.date=2022-12-19&rft.pub=MDPI+AG&rft.issn=1661-6596&rft.eissn=1422-0067&rft.volume=23&rft.issue=24&rft.spage=16206&rft_id=info:doi/10.3390%2Fijms232416206&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_64e2bed5795c4aeca0b01892157bc78e |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon |